Comparing Clinical Outcomes for a Twelve-Month Trial of Zotarolimus- and Everolimus-Eluting Stents in Patients With Coronary Artery Disease: Data From the Thcric Registry Publisher Pubmed



Poorhoseini HR¹ ; Kassaian SE¹ ; Hoseini K¹ ; Saroukhani S² ; Salarifar M¹ ; Alidoosti M¹ ; Nematipour E¹ ; Hajizeinali AM¹ ; Amirzadegan A¹ ; Seyyed Mohammadzadeh MH³ ; Khadem Vatan K⁴ ; Aghajani H¹ ; Sheikh Fathollahi M² ; Farrokheslamlou H⁵ Show Affiliations
Source: Therapeutic Advances in Cardiovascular Disease Published:2016

Abstract

Objectives: New-generation coronary stents including zotarolimus- and everolimus-eluting stents (ZES and EES) have been shown to decrease the risk of restenosis. The purpose of this study was to compare the safety and efficacy of ZES and EES over a 12-month clinical follow up, in routine clinical practice. Methods: This is an observational study in which 1029 consecutive patients treated with ZES (n = 669) or EES (n = 360) were enrolled. The study endpoint was major adverse cardiac events (MACE), defined as cardiac death, nonfatal myocardial infarction (MI), and target lesion or vessel revascularization at 12 months. Results: Follow up was completed among 94.9% of the patients. The overall MACE occurred in 4 (0.6%) and 7 (2.0%) patients in the ZES and EES group, respectively. The occurrence of other cardiac events including nonfatal MI and target vessel or lesion revascularization was 1 (0.2%) versus 1 (0.3%) and 7 (1.1%) versus 5 (1.4%), respectively, in the ZES and EES groups of patients. Despite a slightly lower rate of MACE and cardiac death in the ZES group, the difference between these two groups was not significant (n = 0.064 for overall MACE, p = 0.129 for cardiac mortality, n = 0.999 for nonfatal MI, n = 0.468 for target vessel and n = 0.999 for target lesion revascularization). Conclusions: According to our results, it could be concluded that the difference in the rate of MACE between the ZES and EES groups was not statistically significant at 12-month follow up. © SAGE Publications.